Tag: KDC-MN-074

  • Memantine

    Uncompetitive NMDA receptor antagonist with ancillary 5-HT3 antagonist and alpha-7 nicotinic receptor activity

    A 3,5-dimethyladamantane derivative developed by Merz Pharmaceuticals as a moderate-affinity, voltage-dependent, uncompetitive NMDA receptor open-channel blocker approved for moderate-to-severe Alzheimer’s disease, distinguished from high-affinity NMDA antagonists by rapid off-rate kinetics that permit preservation of physiological synaptic transmission while attenuating tonic excitotoxic glutamatergic signaling.

    Abstract

    Memantine (1-amino-3,5-dimethyladamantane; CAS 19982-08-2; molecular formula C12H21N; molecular weight 179.30) is a moderate-affinity, uncompetitive, voltage-dependent, open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor, approved in the European Union (2002) and the United States (2003) for the treatment of moderate-to-severe Alzheimer’s disease. The compound is an adamantane derivative structurally related to the antiviral agent amantadine, first synthesized and patented by Eli Lilly and Company in 1968 as a potential antidiabetic agent, subsequently identified as possessing central nervous system activity in the early 1970s by Merz Pharmaceuticals, and characterized as an NMDA receptor channel blocker by Bormann in 1989 [1]. The pharmacological distinction of memantine from high-affinity NMDA channel blockers such as phencyclidine, dizocilpine (MK-801), and ketamine rests on three properties: moderate binding affinity (IC50 approximately 1 micromolar at resting membrane potential), strong voltage dependence that ensures rapid unblocking upon physiological depolarization, and fast open-channel blocking and unblocking kinetics (time constant of unblock approximately 5 seconds) [2, 3]. These kinetic properties allow memantine to attenuate the tonic, pathologically elevated glutamatergic signaling associated with excitotoxic neurodegeneration while preserving the transient, high-amplitude synaptic NMDA receptor activation required for long-term potentiation and normal cognitive function. In addition to the primary NMDA receptor mechanism, memantine acts as a non-competitive antagonist of the serotonin 5-HT3 receptor at concentrations comparable to its NMDA receptor affinity (IC50 approximately 1 to 2 micromolar) [4] and as a non-competitive antagonist of the alpha-7 nicotinic acetylcholine receptor (IC50 approximately 0.34 to 5 micromolar depending on assay conditions) [5]. Weak agonist activity at the sigma-1 receptor (Ki approximately 2.6 micromolar) has been reported but is unlikely to contribute at therapeutic plasma concentrations [6]. Pharmacokinetics in humans are characterized by near-complete oral bioavailability (approximately 100 percent), a long plasma elimination half-life of 60 to 80 hours permitting once- or twice-daily dosing, minimal hepatic cytochrome P450-mediated metabolism, and predominantly renal elimination with approximately 48 percent of the administered dose excreted unchanged in urine through pH-dependent tubular reabsorption and active tubular secretion [7, 8]. Two pivotal registration trials established efficacy: the Reisberg et al. (2003) study in 252 patients with moderate-to-severe Alzheimer’s disease demonstrated significant benefit over placebo on the Severe Impairment Battery (SIB) and the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) over 28 weeks [9], and the Tariot et al. (2004) study in 404 patients already receiving stable donepezil demonstrated that the addition of memantine produced significant improvement in cognitive, functional, behavioral, and global measures compared to placebo plus donepezil [10]. Memantine is marketed as Namenda (Forest Laboratories, now Allergan/AbbVie) in the United States, as Axura (Merz) and Ebixa (Lundbeck) in Europe, and under multiple generic names globally. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.